Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review - PubMed
6 hours ago
- #liquid biopsy
- #neurodegenerative diseases
- #long non-coding RNAs
- LncRNAs are crucial in neurodevelopment, homeostasis, and progression of neurodegenerative diseases like Alzheimer's, Parkinson's, ALS, and Huntington's.
- They modulate disease mechanisms including protein misfolding, neuroinflammation, mitochondrial dysfunction, ferroptosis, synaptic failure, and aging processes via epigenetic, transcriptional, and post-transcriptional pathways.
- LncRNAs can serve as liquid biopsy biomarkers in blood, CSF, and extracellular vesicles, offering minimally invasive diagnostic potential.
- Therapeutic targeting of lncRNAs is possible through antisense oligonucleotides, gene editing, and engineered delivery systems.
- Challenges include specificity, validation, blood-brain barrier delivery, and clinical standardization for precision neurology applications.